--
Xtandi – Replacing competitor from Zytiga to Casodex (Bicalutamide) for a
bigger pie in Prostate cancer & Finding its niche in crowded BC market
Xtandi + Zytiga vs. ARN-509 + Zytiga - Who will win the race?
Rising star Anti Androgens – Third generation Antiandrogens- What left for AR-V7 mutants after TOK-001 failure?
Late Stage Prostate Cancer Pipeline drugs – AKT inhibitors or PARP inhibitors or a new MoA combination with Antiandrogen or IO combo - Competing to Xtandi/Zytiga or targeting Xtandi/Zytiga Resistance Population?
Increase in prevalence of Prostate cancer and availability of new treatment options (Zytiga, Xtandi, Cabazitaxel and Xofigo) in last few years has extended role of newer oral Antiandrogens to treat metastatic CRPC patient populations where the unmet need was high. This has expanded WW market size of Prostate cancer drugs to $7b in 2016 from $2.5b in 2011. Now nmCRPC, HSPC and Xtandi/Zytiga resistance population are the markets where in new pipeline drugs are under development.
Reported PhII clinical data of Xtandi, ARN-509 and ODM-201 in nmCRPC when indirectly compared demonstrate the bar is high for ARN-509 to compete against Xtandi in nmCRPC market and while ODM-201 is few years behind in clinical development. While in mHSPC reported clinical results of STAMPEDE study opens door for docetaxel combination approach as standard of care in first line setting.
Download Sample Report @ https://www.wiseguyreports.com/sample-request/924359-prostate-cancer-newer-antiandrogens-and-resistance-population
For more information or any query mail at [email protected]
Around 8 plus drugs are in PhIII development for Prostate cancer treatment and 26 plus drugs are in PhII development (21 small molecules) - success of a few (ARN-509, ODM-201, AZD 5363, GX301) in coming years will expand nmCRPC ($3.5be), mHSPC market ($1be) and Xtandi/Zytiga resistant population ($1be) market by 2023. Longer duration of therapy and high prevalence makes earlier setting market more attractive and bigger for newer options than the late stage if they succeed.
For drugs targeting through androgen pathway - Now trials and clinical development is underway for second and third generation androgen receptor inhibitors (ARN-509, ODM-201, ODM-204, EPI-506, VT-464, TAS-3681 and DR103). While androgen synthesis inhibitors still needs a proof of concept in clinic due to failure of TAK-700 & TOK-001. Expected data from VT-464 (Apr 2017) & ASN-001 will be important to watch to taste the success for this class. Androgen receptor degrader is another MoA in development from a decade and success of in clinic compound GTX-758 (Data expected anytime from now as study completed in March 2016- less likely to succeed) will decide the proof of concept.
Other than pipeline drugs targeting androgen pathway, NCE targeting AKT pathway (AZD5363, Ipatasertib) appears to be more promising to succeed in late stage, while drugs acting through PARP inhibition (Olaparib, Niraparib) still needs a taste of success. Other interesting pipeline asset is LHRH agonist LMIS 50 mg, which is designed to overcome the drawbacks of the commercial depot products containing GnRH agonists by using a proprietary delivery system.
Also 6 therapeutic vaccines are in clinical development to treat prostate cancer. Recently launched PD-L1 IO therapy has increased hope of treating cancer in much safer way. Current ongoing studies of late stage IO mab are in Ph I/II clinical development and would be able to answer of PTEN hypothesis for role of PD-1, PD-L1 inhibitor to treat prostate cancer in coming years.
Resistant development is another challenge with long term use of Xtandi/Zytiga and needs to be addressed by pipeline second/third generation Antiandrogens/ combination approach with IO/PARP/AKT inhibitors to treat mCRPC. Increase in pricing pressure in developed market again put inference on Combination approach unless the advantage is significant and improve the Q0L in earlier setting. Due to that, drugs targeting adjuvant setting has high bar to deliver (Atezolizumab, GX301, Mipsagargin and Olaparib) in the clinical development to add significant value.
This report details current unmet need, changing regulatory requirement, reimbursement challenges & market dynamics of Prostate Cancer drugs. Report mention pipeline Antiandrogens, late stage prostate cancer pipeline drugs/new Mechanism of action & major companies developing Prostate cancer drugs. It also provides insight on clinical development strategy of combination pipeline/marketed drugs & therapeutic competitive landscape to find treatment paradigm fit & market potential of new drugs for treatment of Prostate Cancer
Complete Report Details @ https://www.wiseguyreports.com/reports/924359-prostate-cancer-newer-antiandrogens-and-resistance-population
Table Of Contents – Major Key Points
1. Executive Summary
Antiandrogens- Expanding Role of new Oral Antiandrogens in early treatment armamentarium of Prostate Cancer and Other indications-
Ø Current Role of Oral antiandrogen therapy and its limitations
o nmCRPC and HSPC- Next growth driver of New Oral Antiandrogens – ARN-509 or Xtandi or ODM-201- Who will win the race?
o WW Targeted Patient population and expected Market size expansion of Anti androgens in each stage
o Zytiga patent expiry – Game Changer in Antiandrogen Class
o New Pipeline early stage Antiandrogens
Ø Targeting Xtandi and Zytiga Resistance population- A way to Fast track drug development?
Immuno-Oncology drug –Potential in Prostate Cancer and ongoing combination studies with Antiandrogens & with Pipeline Prostate Cancer drugs
Other Late stage Pipeline drugs for treatment of Prostate Cancer- AKT inhibitors or PARP inhibitors or a new MoA combination with Antiandrogen- Competing to Xtandi/Zytiga or targeting Xtandi/Zytiga Resistance Population?
2. Prostate Cancer
Ø Stages of prostate cancer
Ø Signs and symptoms of prostate cancer
Ø Causes of prostate cancer
Ø Treatment of prostate cancer
Ø Unmet need of prostate cancer
Ø Current market size of prostate cancer
3. Xtandi
Ø Xtandi – current uptake
o Xtandi current US prescription trend and its uptake
§ Xtandi Price issue
o Xtandi uptake in Europe
o Xtandi uptake in Japan
Ø Xtandi- additional opportunities in Prostate Cancer
o Xtandi in nmCRPC- PROSPER study
§ Urology opportunity / Xtandi as a preferred urology drug
§ Xtandi Market Potential in nmCRPC
• Xtandi Price Issue in nmCRPC
• Xtandi duration of therapy in nmCRPC
o Xtandi – additional clinical trials in Prostate Cancer
§ Xtandi in M1 Hormone Sensitive patients
§ Xtandi in Mo Hormone Sensitive patients
§ Xtandi other ongoing clinical studies
o Xtandi with Pfizer early stage Prostate cancer Pipeline drug
Ø Xtandi in Other Indications
o Xtandi Potential in Breast Cancer
o Xtandi in Hepatocellular Carcinoma
Ø Xtandi in combination with New pipeline drugs
Ø Xtandi with IO combo- please refer chapter no. 7
………..CONTINUED
For more information or any query mail at [email protected]
Buy This Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=924359
Contact Info:
Name: Norah Trent
Email: Send Email
Organization: WiseGuy Research Consultants Pvt Ltd.
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028
Phone: +1-646-845-9349
Website: https://www.wiseguyreports.com
Release ID: 168179
Google
RSS